Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: poodle who wrote (1722)	1/15/1998 3:21:00 PM
From: Dr. Voodoo	Read Replies (1) \| Respond to of 7041

Poodle, If I understand your question correctly and I'll phrase it another way-- What are they looking at in this paper from looking at the abstract? I have not read the full paper, I would suggest this if you are really interested in knowing the facts. From the abstract, they are investigating the use of both phentolamine and papaverine separately and combined. The results were positive in 13 out of 15 patients tested when a combination of papaverine and phenolamine were used. 6 of the 15 patients were found to have positive results when injected with papaverine alone 1 of the 15 patients was found to have a positive result when injected with phentolamine alone. Papaverine causes problems after long term use. I don't know the source of the problem or what the deleterious effects are.